# US 2020/0347361 A1 · Methods of Primary Tissue Culture and Drug Screening Using Autologous Serum and Fluids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0347361 A1
- Document ID: US20200347361A1
- Status: Published application
- Kind: A1
- Application number: 16/921,007
- Filed: 2020-07-06
- Published: 2020-11-05
- Earliest claimed: 2016-03-21
- Assignees: Yao Tang
- Inventors: Yao Tang
- Web page: https://patentgrep.com/patent/US20200347361A1

## CPC

- C12N 5/0694: {Cells of blood, e.g. leukemia cells, myeloma cells}
- C12N 5/0693: {Tumour cells; Cancer cells}
- C12N 2500/84: from mammals
- C12N 2503/02: Drug screening
- C12N 2509/00: Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N 2509/10: Mechanical dissociation
- C12N 2513/00: 3D culture
- C12N 2533/52: Fibronectin; Laminin
- C12N 2533/54: Collagen; Gelatin
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides methods for culturing primary cells and tissues from a subject in the presence of the subject's own serum, ascites or pleural effusion fluid. Methods of treating cancer, and screening for the effectiveness or toxicity of drugs are also provided herein.

## Claims

### Claim 1

A method for the primary culturing of solid tumor tissue from a subject, using the following steps in the order shown:
A. obtaining the tissue from the subject;
B. obtaining serum from the subject;
C. embedding the tissue in a three dimensional autologous matrix by
a) mixing one or more matrix proteins with serum from the subject at a ratio of approximately 1:1 to make an autologous matrix,
b) coating the surface of a culture well or plate with a layer of the autologous matrix,
c) placing the tissue onto the coated surface,
d) adding a second layer of the autologous matrix onto the tissue, such that the tissue is immersed in the autologous matrix; and
D. culturing the embedded tissue in a medium consisting essentially of 100% serum (v/v) from the subject.

### Claim 2

A method for the primary culturing of cancer cells from the ascites or pleural effusion fluid of a subject, using the following steps in the order shown:
A. obtaining the fluid from the subject;
B. isolating the cells from the fluid while retaining the cell-free fluid;
C. filtering the cell-free fluid to prevent protein clotting;
D. building a three dimensional autologous structure by
a) mixing one or more matrix proteins with the filtered, cell-free fluid at a ratio of approximately 1:1 to make an autologous matrix,
b) coating the surface of a culture well or plate with the autologous matrix,
E. seeding the isolated cells from step B onto the coated surface of step D; and
F. culturing the seeded cells in a medium consisting essentially of 100% cell-free fluid (v/v) from step C.

### Claim 3

A method for culturing circulating tumor cells (CTC) from the peripheral blood of a subject, using the following steps in the order shown:
A. obtaining blood from the subject;
B. isolating a cell population containing both CTC and the peripheral blood mononuclear cells (PBMC) from the subject's blood, while retaining the serum;
C. building a three dimensional autologous structure by
a) mixing one or more matrix proteins with the serum from step B at a 1:1 ratio to make an autologous matrix,
b) coating the surface of a culture well or plate with the autologous matrix,
D. seeding the cells from step B onto the coated surface of step C,
E. culturing the seeded cells in a medium consisting essentially of 100% serum (v/v) from the subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein the tissue from a subject is prepared by mechanical digestion.

### Claim 5 (depends on 2, 3)

The method of claim 2 or 3 wherein the cells are isolated using density gradient centrifugation.

### Claim 6 (depends on 1, 2, 3)

The method of claim 1, 2 or 3 wherein the thickness of the layer coating the well or plate is approximately one to four millimeters.

### Claim 7 (depends on 1, 2, 3)

The method of claim 1, 2 or 3 wherein the one or more matrix proteins comprises laminin, enactin, collagen, and heparan sulfate proteoglycans.

### Claim 8 (depends on 1, 2, 3)

A method for the concurrent testing of the toxicity and effectiveness of candidate cancer therapies to select the treatment that is most suitable for a particular subject, comprising:
A. culturing the tissue or cells from the subject according to the method of claim 1, 2 or 3, depending on the type of sample to be tested;
B. obtaining blood from the subject, isolating PBMC from the blood by density gradient centrifuge, and maintaining the isolated PBMC in a medium consisting essentially of 100% serum (v/v) from the subject;
C. applying the candidate therapy in parallel to the culture of step A and to the PBMC from step B, following the same treatment protocol;
D. assessing the effectiveness of the candidate treatment against the cancerous cells or tissue in the culture from step A, and measuring the toxicity of the treatment to the PBMC from step B;
E. selecting the therapy having the highest effectiveness against the cancer, and an acceptable toxicity to the PBMC from the subject.

### Claim 9 (depends on 8)

The method of claim 8, step C wherein the candidate therapy comprises, but is not limited to, any chemical agent, targeted gene therapy product, immunotherapy product, radiation procedure or other anti-cancer regimen, applied singly or concurrently.

### Claim 10 (depends on 8)

The method of claim 8, step D, wherein the effectiveness and toxicity of the candidate therapy is measured by various cell viability assays including, but not limited to, WST-8 cell counting kit, colorimetric tetrazolium reagents (MTS, XTT, WST-1), reazurin reduction and protease substrates-generated fluorescent signal detection, luminogenic ATP assay, real-time monitoring of live cell growth, and immunohistochemistry.
